COMUNICADO: ViiV Healthcare Announces Superior Efficacy of Dolutegravir Versus Lopinavir/Ritonavir in Second-line HIV Treatment in R

 

COMUNICADO: ViiV Healthcare Announces Superior Efficacy of Dolutegravir Versus Lopinavir/Ritonavir in Second-line HIV Treatment in R

Contador
Publicado 25/07/2017 15:07:57CET

ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline and Pfizer dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of becoming infected with HIV. Shionogi joined in October 2012. The company's aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline, and commitment, please visit http://www.viivhealthcare.com . About GSK    GSK - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit http://www.gsk.com. Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Principal risks and uncertainties' in the company's Annual Report on Form 20-F for 2016. Photo: http://photos.prnewswire.com/prnh/20160223/336449LOGO

CONTACT: ViiV Healthcare Media enquiries: Sébastien Desprez (on site atIAS), 25 Jul. (0) - 20 8380 6275. Patricia O'Connor, +44(0)208 047 5982. MarcMeachem, +1 919 483 8756. GSK Global Media enquiries: David Daley, +44(0)208047 2615. Kathleen Cuca, +1 215 859 1922. GSK US Media enquiries: MaryAnne Rhyne, +1 919 483 0492. Sarah Spencer, +1 215 751 3335.Analyst/Investor enquiries: Sarah Elton-Farr +44(0)20 8047 5194. GaryDavies, +44(0)20 8047 5503. James Dodwell, +44(0)20 8047 2406. SarahWebster, +44(0)20 8047 0246. Tom Curry, +1 215 751 5419. Jeff McLaughlin,+1 215 751 7002

Mejora la comunicación de tu empresa con Europa Press Comunicación

Mejora la comunicación de tu empresa con Europa Press Comunicación

La actualidad más visitada en EuropaPress logo: La actualidad más vista
Esta web utiliza cookies propias y de terceros para analizar su navegación y ofrecerle un servicio más personalizado y publicidad acorde a sus intereses. Continuar navegando implica la aceptación de nuestra política de cookies -
Uso de cookies